Raphael Pharmaceutical Inc. 8-K

What Happened
Raphael Pharmaceutical Inc. (RAPH) filed an 8-K reporting the voluntary resignations of Ajay Kumar Dhadha as Chairman and Director effective June 30, 2026, and Guy Ofir as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. The filing states neither resignation resulted from any disagreement with the company regarding operations, policies, practices, financial reporting, management, or the Board. Effective July 16, 2026, the company appointed Uri Tadelis as Chief Financial Officer.

Key Details

• Ajay Kumar Dhadha resigned as Chairman of the Board and Director, effective June 30, 2026.
• Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director, effective July 16, 2026.
• Uri Tadelis was appointed Chief Financial Officer, effective July 16, 2026.
• The company disclosed that neither resignation was due to any disagreement with the company on operational or reporting matters (Item 5.02).

Why It Matters
Changes in senior leadership—especially the CFO and Board chair—are material for investors because they affect corporate governance, financial oversight, and strategic continuity. The appointment of a new CFO the same day as the prior CFO’s resignation helps limit a potential gap in financial leadership. The company’s explicit statement that the departures were not due to disagreements reduces immediate regulatory or governance concern, but investors may watch for further disclosures (e.g., background, succession plans, or employment arrangements) that could affect near-term execution or investor confidence.